Aldeyra Therapeu (ALDX)
$1.89 +0.47 (33.10%)Market Cap | 317.65M |
Revenue (ttm) | 0.00 |
Net Income (ttm) | -55.85M |
EPS (ttm) | N/A |
PE Ratio | 0.00 |
Forward PE | N/A |
Profit Margin | 0.00% |
Debt to Equity Ratio | 0.21 |
Volume | 12,925,519 |
Avg Vol | 1,116,820 |
Day's Range | N/A - N/A |
Shares Out | 59.71M |
Stochastic %K | 5% |
Beta | 0.94 |
Analysts | Strong Sell |
Price Target | $9.86 |
Latest News on ALDX

Apr 4, 2025, 10:00 AM EDT - 6 hours ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out



Apr 3, 2025, 12:34 PM EDT - 1 day ago
ALDX BREAKING NEWS: BFA Law Announces an Investigation into Aldeyra Therapeutics, Inc. 75% Stock Drop; Investors are Notified to Contact BFA Law

Apr 3, 2025, 11:58 AM EDT - 1 day ago
ALDX BREAKING NEWS: Aldeyra Therapeutics, Inc. 75% Stock Drop Triggers Securities Investigation; Contact BFA Law if You Lost Money (NASDAQ:ALDX)


Apr 3, 2025, 9:37 AM EDT - 1 day ago
FDA Rejects Aldeyra's Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns


Mar 10, 2025, 7:00 AM EDT - 25 days ago
Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference

Feb 4, 2025, 7:00 AM EST - 2 months ago
Aldeyra Therapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Dec 2, 2024, 7:00 AM EST - 4 months ago
Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference

Nov 18, 2024, 7:00 AM EST - 4 months ago
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement

Nov 14, 2024, 7:00 AM EST - 5 months ago
Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 14, 2024, 5:31 AM EST - 5 months ago
Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects

Oct 31, 2024, 7:00 AM EDT - 5 months ago
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting

Oct 3, 2024, 7:00 AM EDT - 6 months ago
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Sep 5, 2024, 7:00 AM EDT - 7 months ago
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 3:49 PM EDT - 7 months ago
Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership

Aug 8, 2024, 12:30 PM EDT - 8 months ago
Aldeyra's New Eye Drug Shows Positive Results In FDA-Approved Study, Stock Jumps Over 30%

Aug 8, 2024, 7:00 AM EDT - 8 months ago
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Aug 7, 2024, 4:01 PM EDT - 8 months ago
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap

Jun 20, 2024, 7:00 AM EDT - 10 months ago
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

Jun 13, 2024, 7:00 AM EDT - 10 months ago
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Jun 10, 2024, 1:25 PM EDT - 10 months ago
Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission

May 29, 2024, 7:00 AM EDT - 11 months ago
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference



Apr 18, 2024, 7:00 AM EDT - 1 year ago
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024

Mar 28, 2024, 7:00 AM EDT - 1 year ago
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

Mar 24, 2024, 12:46 AM EDT - 1 year ago
Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie

Feb 6, 2024, 7:00 AM EST - 1 year ago
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 28, 2024, 2:56 AM EST - 1 year ago
Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects

Jan 4, 2024, 7:00 AM EST - 1 year ago
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases




Nov 1, 2023, 7:05 AM EDT - 1 year ago
Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap